Physician profile
Alfred Johnson
NPI 1144316431
$933.24
in general payments reported to CMS, 2019-2025
25 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $139 · 2021: $92.46 · 2022: $157 · 2023: $191 · 2024: $124 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.97 | 2021-2025 | |
| Exact Sciences Corporation | $98.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $83.02 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $73.03 | 2023 | Farxiga |
| Allergan, INC. | $45.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.15 | 2020-2025 | Arexvy, Shingrix |
| Almatica Pharma LLC | $39.81 | 2022-2023 | Gralise, Loreev Xr |
| Sunovion Pharmaceuticals INC. | $37.19 | 2020 | |
| Novo Nordisk INC | $34.38 | 2022-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $28.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.15 | 2019-2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $28.13 | 2019 | |
| Csl Behring | $25.45 | 2025 | Andembry |
| Abbott Laboratories | $23.06 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.02 | 2025 | |
| Astellas Pharma US INC | $21.55 | 2023 | Veozah |
| Hologic Sales and Service, LLC | $20.72 | 2024 | Aptima, Third Wave, Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $20.59 | 2023 | Gvoke Hypopen |
| Gilead Sciences, INC. | $19.82 | 2022 | |
| Viiv Healthcare Company | $14.76 | 2023 | Rukobia |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2024 | Zoryve |
| Lilly USA, LLC | $13.35 | 2023 | Jardiance |
| Amarin Pharma, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.